Skin IrritationNCT01887808
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
A study of Skin Irritation, run by Galderma R&D.
Trial summary
Determine if Cetaphil DermaControl Oil Control Moisturizer SPF 30 proves to be a contact sensitizer or irritant in certain individuals Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Irritation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- Dec 2012to Jan 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Not currently under a doctor's care
- Free of dermatological or systemic disorder which would interfere with the results
- Free of any acute or chronic disease
- Will complete a preliminary medical history form and are in general good health
- Can read, understand, and sign informed consent
Who cannot join
- Under 18 years old
- Currently under doctor's care
- Currently taking any medication
- History of acute or chronic disease
- Diagnosed with chronic skin allergies
- Pregnant or lactating
About this study
Official title: Cetaphil Dermacontrol Oil Control Moisturizer SPF 30- 100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)
Determine if Cetaphil DermaControl Oil Control Moisturizer SPF 30 proves to be a contact sensitizer or irritant in certain individuals
- Conditions
- Skin Irritation
- Being tested
- Cetaphil DermaControl Oil Control Moisturizer SPF 30
- Keywords
- Determine, Hypoallergenicity, Cetaphil DermaControl Oil Control Moisturizer SPF 30
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cetaphil DermaControl Oil Control Moisturizer SPF 30Other
| Study group | Role | What they receive |
|---|---|---|
| Cetaphil DermaControl Oil Control Moisturizer SPF 30 | Experimental | All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30 Receives: Other: Cetaphil DermaControl Oil Control Moisturizer SPF 30 |
What is being measured
The primary outcome is the main question the study is designed to answer.
area of erythema and edema to test reaction of skin to product
9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks will be conducted to test the reaction of the skin to the test product
Measured: 3 consecutive weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2013 (estimated)
- Study startDec 2012
- Primary completionJan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin IrritationStudies of the same condition, open and under way.
- More trials run by Galderma R&DThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Galderma R&D
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Mayya Tastene, MD, Principal investigator, AMA Laboratories, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01887808
- Sponsor's protocol ID
- GLI.04.SRE.US10232b
- Status last verified
- Jun 2013
- First submitted
- 21 Jun 2013
- Last updated
- 29 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cetaphil Dermacontrol Oil Control Moisturizer SPF 30- 100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)
- ClinicalTrials.gov ID
- NCT01887808
- Acronym / sponsor ID
- GLI.04.SRE.US10232b
- Conditions
- Skin Irritation
- Keywords
- Determine, Hypoallergenicity, Cetaphil DermaControl Oil Control Moisturizer SPF 30
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Galderma R&DIndustry (pharma, biotech, devices)
- Study start
- Dec 2012
- Primary completion
- Jan 2013 (actual)
- First posted
- 27 Jun 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Determine if Cetaphil DermaControl Oil Control Moisturizer SPF 30 proves to be a contact sensitizer or irritant in certain individuals
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cetaphil DermaControl Oil Control Moisturizer SPF 30 | Experimental | Other: Cetaphil DermaControl Oil Control Moisturizer SPF 30All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Not currently under a doctor's care
- Free of dermatological or systemic disorder which would interfere with the results
- Free of any acute or chronic disease
- Will complete a preliminary medical history form and are in general good health
- Can read, understand, and sign informed consent
Key exclusion criteria (6 listed)
- Under 18 years old
- Currently under doctor's care
- Currently taking any medication
- History of acute or chronic disease
- Diagnosed with chronic skin allergies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cetaphil DermaControl Oil Control Moisturizer SPF 30 | Other | Cetaphil DermaControl Oil Control Moisturizer SPF 30 |
Primary outcome
area of erythema and edema to test reaction of skin to product
Time frame: 3 consecutive weeks
9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks will be conducted to test the reaction of the skin to the test product
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2022.
Related trials for Skin Irritation
RecruitingObservational study
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
IBS (Irritable Bowel Syndrome), Rosacea
Active, not recruiting
Shaving Satisfaction in Males With Skin Irritation From Shaving
Pseudofolliculitis Barbae
Recruiting
IBS Skin Patch Test Food Allergy Study
Irritable Bowel Syndrome
Not yet recruiting
Acupuncture Combined With Transcutaneous Electrical Acupoint Stimulation for Constipation-Predominant Irritable Bowel Syndrome With Anxiety State
IBS, Constipation Predominant, Anxiety State
Not yet recruiting
Suture Choice for Ostomy Creation
Ostomy - Ileostomy or Colostomy, Stoma Complications
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mayya Tastene, MD principal investigator
AMA Laboratories, Inc.
Questions about this trial
What is this clinical trial studying?
A study of Skin Irritation, run by Galderma R&D.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
area of erythema and edema to test reaction of skin to product (time frame: 3 consecutive weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2022.